TGF‐β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation

TGF‐β1 mediates pathologic changes of secondary lymphedema by promoting fibrosis and inflammation

Abstract Background Secondary lymphedema is a common complication of cancer treatment, and previous studies have shown that the expression of transforming growth factor‐beta 1 (TGF‐β1), a pro‐fibrotic and anti‐lymphangiogenic growth factor, is increased in this disease. Inhibition of TGF‐β1 decrease...

Full description

Bibliographic Details
Main Authors: Jung Eun Baik, Hyeung Ju Park, Raghu P. Kataru, Ira L. Savetsky, Catherine L. Ly, Jinyeon Shin, Elizabeth M. Encarnacion, Michele R. Cavali, Mark G. Klang, Elyn Riedel, Michelle Coriddi, Joseph H. Dayan, Babak J. Mehrara
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Clinical and Translational Medicine
Subjects:
fibrosis
inflammation
pirfenidone
TGF‐β
Online Access:https://doi.org/10.1002/ctm2.758

Internet

https://doi.org/10.1002/ctm2.758

Similar Items